Senseonics Holdings, Inc. (SENS): Price and Financial Metrics


Senseonics Holdings, Inc. (SENS)

Today's Latest Price: $0.46 USD

0.00 (0.69%)

Updated May 22 8:00pm

Add SENS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

SENS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for SENS is -2.46 -- better than only 4% of US stocks.
  • With a year-over-year growth in debt of 120.8%, Senseonics Holdings Inc's debt growth rate surpasses 88.36% of about US stocks.
  • Senseonics Holdings Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -105.93%, greater than the shareholder yield of merely 4.54% of stocks in our set.
  • Stocks that are quantitatively similar to SENS, based on their financial statements, market capitalization, and price volatility, are RWLK, INSM, AQST, TTOO, and CPSI.
  • SENS's SEC filings can be seen here. And to visit Senseonics Holdings Inc's official web site, go to www.senseonics.com.
SENS Daily Price Range
SENS 52-Week Price Range

SENS Stock Price Chart More Charts


SENS Price/Volume Stats

Current price $0.46 52-week high $2.24
Prev. close $0.46 52-week low $0.45
Day low $0.45 Volume 2,007,758
Day high $0.48 Avg. volume 2,280,207
50-day MA $0.60 Dividend yield N/A
200-day MA $0.93 Market Cap 103.67M

Senseonics Holdings, Inc. (SENS) Company Bio


Senseonics Holdings, Inc. focuses on the design, development, and commercialization of glucose monitoring systems for people with diabetes. The company was founded in 1996 and is based in Germantown, Maryland.


SENS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

SENS Latest Social Stream


Loading social stream, please wait...

View Full SENS Social Stream

Latest SENS News From Around the Web

Below are the latest news stories about Senseonics Holdings Inc that investors may wish to consider to help them evaluate SENS as an investment opportunity.

Local Coverage Determination Proposed for Implantable Continuous Glucose Monitors by Medicare Administrative Contractors

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring system for people with diabetes, announced today that three Medicare Administrative Contractors (MACs), Palmetto, First Coast Service Options (FCSO) and Novitas have removed implantable continuous glucose monitors (CGM) such as Eversense from their non-coverage policy. In addition, FCSO and Novitas have each published proposed Local Coverage Determinations (LCD) for implantable CGMs. This now enables the MACs to adjudicate claims for the Eversense CGM system submitted by healthcare providers for their Medicare beneficiaries as a Part B physician service.

Yahoo | May 14, 2020

Senseonics Holdings (SENS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research | May 7, 2020

Senseonics Announces Positive Coverage Decision for Eversense CGM from Several Blue Cross Blue Shield Plans

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that three more Blue Cross Blue Shield plans are now providing coverage for the Eversense® CGM System, effective immediately. These recent coverage decisions add to the growing number of payers who are writing Evers

Business Wire | May 6, 2020

Senseonics Eversense® Sensor Receives MRI Conditional Approval in Europe

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced regulatory approval that the Eversense® XL Sensor is no longer contraindicated for MRI which means that the sensor does NOT need to be removed from under the skin during MRI scanning. During scanning the external Ev

Business Wire | April 28, 2020

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2019. Recent Highlights & Accomplishments: Fourth Quarter total net revenue of $9.0 million OUS net revenue of $8.1 million U.S. net revenue of $0.8

Business Wire | March 12, 2020

Read More 'SENS' Stories Here

SENS Price Returns

1-mo -23.89%
3-mo -70.13%
6-mo -57.41%
1-year -77.23%
3-year -72.29%
5-year N/A
YTD -49.78%
2019 -64.63%
2018 -2.63%
2017 -0.37%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8132 seconds.